Tag Archives | gene therapy

Biotech is Hot Sparked By Biotech M&A Deals for Juno and Bioverativ…Update-1

Update-1 Jan 23, 2018… Biotech Breakout Rally Continues The biotech rally cruised on to the second day with the smaller cap, equal weighted XBI moving up 2% to $95.82 a 12 month high. The large cap weighted IBB followed up 1.12% to $116.81 also a 12 month high. The media especially CNBC trucked right along […]

Continue Reading 0

Rayno Biopharma Portfolio 2017 Summary Performance

2/2/18 Update After Sell-Off Cautious on Amgen (AMGN) after earnings release but looks better than the IBB if you are bullish on biotech. XBI remains a top ETF pick but given weak momentum and volatility is currently more of a trade not a buy at these levels of $93. Abbvie (ABBV) recovery today to $117 […]

Continue Reading 0

M&A Theme Continues To Boost Biotech Stocks

M&A Boosts Biotech Stocks For Third Day Gilead Sciences (GILD) and bluebird bio (BLUE) Both Soar Today  Biotech Sector Back to 2017 Highs The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and  6.48% over five days to $323.76 approaching its […]

Continue Reading 0

BIOtech Breakout: Healthcare Stocks Lead the Way…Update-1

6/27/17 Red Screen Day: Sell-Off in Biotechs Possibly Due to Senate Delay in Healthcare Vote IBB down 1.54% at $314.80. Momentum stocks are weak; NASDAQ down 1.2%. Take profits on XBI trade at $78 range after 34% move YTD. Allow time for arm twisting by Republicans after JY 4. ======== Biotech Breakout Continues with Larger […]

Continue Reading 0

Rayno Life Science Portfolio 2017

Update-1 6/27/17 With the XBI up 34% YTD at $79.34, take a little off for future trades. ===== Rayno Life Science Portfolio 2017 YTD 6/15 Top winners YTD: BLUE up 78.9%,FMI up 121.5%,RHHBY up 13%, ABBV up 12.7%. Top Losers YTD: GILD down 9.5%, BMY down 7%. XBI up 20.9%, our top pick for aggressive […]

Continue Reading 0

Biotechs Mired in a Trading Range: Breakout Delayed…Update-3

Update-3…ASCO Movers Today 5/18:  IBB up 1.28% to $292.27, XBI up 2% to $70. Nice follow through in biotech after a nasty day on 5/17 attributed to ASCO and a move away from the “Trump Trade” (industrials and materials).  Mid-caps and small caps were very strong. Large Caps: MRK up 1.35%,REGN up 2.38%. Mid Caps: […]

Continue Reading 0

Rayno Biopharma Portfolio Update: BLUE FMI IBB…Update-1

Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79. Large caps were mainly in the red except ALXN,BIIB […]

Continue Reading 2

Market Reversal in Biotech But Healthcare Stocks Are Still Muddled

Market Reversal in Biotech Offers Bullish Set-Up After one of the worst down days in months yesterday biotech stocks broadly reversed today giving a short term “nibble” signal. The macro environment got support from economic data as well with upward Q3 GDP revisions to 3.2% and higher consumer confidence data. The economy now has the […]

Continue Reading 0

Trump Biotech Rally: After Comey Sell-Off and Since Election

  Trump Biotech Rally-Have a Balanced Portfolio Everybody who invests in biotech knows there has been a Trump biotech rally since his election as you can see from the chart and data below. Many opinions and analysis were given for the rally.Some pundits say it is because the end of the grueling election has removed […]

Continue Reading 0

Rayno 2016 Life Science Portfolio Update…BLUE,IBB…Update-2

Update-1… See Caution 9/29 Update-2…See Rayno Biobeat for updates after Trump Rally. For overweighting biotechs in a portfolio consider XBI instead of IBB to get mid and small cap exposure. ——– Rayno Portfolio Outperforms the Market Biotech stocks are near their intermediate highs but still down in 2016 : IBB at $295 down 12.78% and […]

Continue Reading 0